A. L. Fallacara

发表

Design, synthesis, and biological evaluation of pyrazolo[3,4-d]pyrimidines active in vivo on the Bcr-Abl T315I mutant.

M. Radi, C. Tintori, F. Musumeci, 2013, Journal of medicinal chemistry.

Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of Influenza Virus PA-PB 1 interaction

Arianna, F. Musumeci, A. L. Fallacara, 2018 .

Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors

F. Musumeci, A. L. Fallacara, S. Schenone, 2017, Expert opinion on therapeutic patents.

4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.

I. D. de Esch, C. Tintori, A. L. Fallacara, 2016, Journal of medicinal chemistry.

Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction.

F. Musumeci, A. L. Fallacara, S. Schenone, 2018, European journal of medicinal chemistry.

Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.

G. Biamonti, M. Radi, C. Tintori, 2015, Journal of medicinal chemistry.

The Fight against the Influenza A Virus H1N1: Synthesis, Molecular Modeling, and Biological Evaluation of Benzofurazan Derivatives as Viral RNA Polymerase Inhibitors

C. Tintori, A. L. Fallacara, I. Laurenzana, 2014, ChemMedChem.

High-throughput docking for the identification of new influenza A virus polymerase inhibitors targeting the PA-PB1 protein-protein interaction.

Cristina Tintori, Maurizio Botta, Anna Lucia Fallacara, 2014, Bioorganic & medicinal chemistry letters.

Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.

F. Musumeci, C. Brullo, A. L. Fallacara, 2017, Current Medicinal Chemistry.

An Update on JAK Inhibitors.

F. Musumeci, C. Brullo, A. L. Fallacara, 2019, Current medicinal chemistry.

Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.

F. Musumeci, C. Brullo, A. L. Fallacara, 2017, European journal of medicinal chemistry.

3‐Arylidene‐N‐hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity

A. L. Fallacara, M. Botta, F. Zunino, 2016, ChemMedChem.

Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line

G. Russo, R. Parenti, A. L. Fallacara, 2019, International journal of molecular sciences.

A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor

C. Zamperini, E. Dreassi, A. L. Fallacara, 2019, Cancers.

The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma

C. Zamperini, E. Dreassi, A. L. Fallacara, 2022, Biomedicines.

Insight into the Allosteric Inhibition of Abl Kinase

Cristina Tintori, Maurizio Botta, Anna Lucia Fallacara, 2014, J. Chem. Inf. Model..

Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.

F. Musumeci, C. Zamperini, A. L. Fallacara, 2018, Bioorganic & medicinal chemistry letters.

Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.

M. Radi, C. Tintori, F. Musumeci, 2015, Journal of medicinal chemistry.

Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors

F. Musumeci, A. L. Fallacara, S. Schenone, 2018, Molecules.

Inhibitors of Tau-Phosphorylating Kinases

A. L. Fallacara, S. Schenone, M. Botta, 2017 .

Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors

A. L. Fallacara, S. Schenone, A. Angelucci, 2015, ChemMedChem.

Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.

A. L. Fallacara, S. Schenone, M. Botta, 2017, MedChemComm.

Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.

F. Musumeci, C. Zamperini, E. Dreassi, 2017, Journal of medicinal chemistry.

One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.

A. L. Fallacara, M. Botta, H. Abdel‐Aziz, 2018, Future medicinal chemistry.

Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.

F. Musumeci, A. L. Fallacara, E. Crespan, 2019, European journal of medicinal chemistry.

Pyrazolo[3,4-d]pyrimidines-loaded human serum albumin (HSA) nanoparticles: Preparation, characterization and cytotoxicity evaluation against neuroblastoma cell line.

C. Zamperini, E. Dreassi, A. L. Fallacara, 2017, Bioorganic & medicinal chemistry letters.

Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells.

A. L. Fallacara, M. Botta, A. Gure, 2020, ACS medicinal chemistry letters.

SMALL MOLECULES SOLVING BIG PROBLEMS: PRESENT AND FUTURE OF DRUG DISCOVERY

Maurizio Botta, Anna Lucia Fallacara, Iuni Margaret Laura Tris, 2018, Journal of the Siena Academy of Sciences.

Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.

C. Zamperini, E. Dreassi, A. L. Fallacara, 2021, European journal of medicinal chemistry.

Protein-protein interactions and human cellular cofactors as new targets for HIV therapy.

C. Tintori, A. L. Fallacara, S. Schenone, 2014, Current opinion in pharmacology.

Probing the binding site of abl tyrosine kinase using in situ click chemistry.

C. Tintori, A. L. Fallacara, M. Botta, 2013, ACS medicinal chemistry letters.

A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.

M. Radi, C. Tintori, A. L. Fallacara, 2016, Bioorganic & medicinal chemistry letters.